Clinical Trial Update: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update investigates initial therapy with zanubrutinib and venetoclax, with obinutuzumab added based on response, for chronic lymphoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING